STM Journals Peer-reviewed research from Consortium e-Learning Network

Research & Reviews: A Journal of Pharmacognosy

Unani Medicinal Plants with Anti-HIV Potential

  1. Qamar Uddin
  2. Ahmad Sayeed
  3. Khalid Mehmood Siddiqui

Abstract

Acquired immune deficiency syndrome (AIDS) is a result of human immunodeficiency virus (HIV) infection which subsequently leads to severe suppression of immune functions. AIDS is a significant threat to the health of mankind as there is no curative treatment for HIV infection and AIDS. Current anti-retroviral therapies (ART) are quite expensive or unaffordable by common man and are associated with adverse effects and rapid emergence of drug resistance. Therefore, the search for a new, safe, effective and affordable anti-HIV/AIDS drug is a global concern. The aim of this review is to summarize research findings for Unani medicinal plants, which are endowed with the ability to inhibit HIV. The present paper describes 22 Unani medicinal plants which have been shown to inhibit infectivity and replication of HIV. Unani medicinal plants which are most effective and the most commonly studied in relation to AIDS are: Andrographis paniculata, Croton tiglium, Curcuma longa, Hypericum perforatum, Momordica charantia, Phyllanthus urinaria, Polyalthia suberosa and Terminalia chebula. However, clinical studies of these herbs need to be conducted for possible alternative medical treatment of HIV infection and AIDS. Keywords: Unani medicine, AIDS, HIV RNA, anti-HIV active compounds

References (56)

  1. McPhee SJ, Papadakis MA, Tierney LM. Current Medical Diagnosis and Treatment (CMDT), 46th Edn. McGraw- Hill Company, USA: 2007; 1346–77p.
  2. Kumar P , Clark M. Kumar & Clark’s Clinical Medicine , 7th Edn. Saunders, Elsevier, USA: 2009; 184–205p.
  3. Williams NS, Bulstrode CJK, O’Connell PR. Bailey & Love’s Short Practice of Surgery, 26th Edn. CRS Press, Taylor & Francis Group, Boca Raton, US: 2013; 66–7p.
  4. Kliegman RM, Stanton BF, St. Geme JW, Schor NF, Behrman RE. Nelson Textbook of Pediatrics , 19th Edn. Elsevier India Private Limited, New Delhi: 2012; 1157– 77p.
  5. Colledge NR, Walker BR, Ralston SH . Davidson’s Principles and Practice of Medicine, 21st Edn. Churchill Livingstone, Elsevier Ltd, Philadelphia: 2010; 383–408p.
  6. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J . Harrison’s Principles of Internal Medicine , 18th Edn. Vol I, McGraw –Hill Companies, USA: 2012; 1500–87p.
  7. Kumar V, Abbas AK, Fausto LD. Robbins & Cotran Pathologic Basis of Disease, 7th Edn. Saunders, Elsevier, USA: 2006; 245–58p.
  8. Greenwood D, Slack RCB, Peutherer JF. Medical Microbiology, 16th Edn. Elsevier India Private Limited, New Delhi: 2006; 527–38p.
  9. Paniker CKJ. Ananthanarayan and Paniker’s Textbook of Microbiology , 7th Edn. Orient Longman Pr ivate Limited, Hyderabad, India: 2005; 582–98p.
  10. Cook GC, Zumla A. Manson’s Tropical Diseases, 21st Edn. Saun ders, Elsevier Sciences, London: 2003; 401–25p.
  11. Wyngaarden JB, Smith LH, Bennett JC. Cecil Textbook of Medicine , 19th Edn. W.B. Saunders Companies, Philadelphia: 1992; 1908–70p.
  12. Venes Donald, Art hur Biderman, Evelyn Adler. Taber’s Cyclopedic Medical Dictionary, 21st Edn. Jaypee Brothers Medical Publishers Private Limite d, New Delhi: 2010; 64–7p.
  13. Tamura S, Shiomi A, Kinmura T. Halogenated analog of 1’ acetoxychavicol acetate rev –export inhibitor from Alpinia galanga, designed from mechanism of action, Bioorg & Med Chem Lett: 2010; 20(7): 2082–5p.
  14. Tewtrakul S, Subhadhirasakul S, Cheenpracha S, et al. HIV–1 protease and HIV–1 integrase inhibitory substances from Eclipta prostrate, Phytother Res : 2007; 21(11): 1092–5p.
  15. Calabrese C, Berman SH, Babish JG, et al. A phase I trial of andrographolide in HIV positive patients and normal volunteers, Phytother Res : 2000; 14 (5): 333–8p.
  16. Reddy VL, Reddy SM, Ravikanth V, et al. New bis–andrographolide ether from Andrographis paniculata Nees and evaluation of anti–HIV activity. Nat Prod Res. 2005; 19 (3): 223–30p.
  17. Chang RS, Ding L, Chen GQ, et al. Dehydroandrographolide succinic acid monoester as an inhibitor against HIV. Proc Soc Exp Biol Med . 1991; 197: 59– 66p.
  18. Hauber I, Hohenberga H, Holstermanna B, et al. The main green tea polyphenol epigallocatechin–3–gallate counteracts semen–mediated enhancement of HIV infection. PNAS USA : 2009; 106(22): 9033–8p. Research & Reviews: A Journal of Pharmacognosy Volume 1, Issue 2 RRJoPC (2014) 11-22 © STM Journals 2014. All Rights Reserved Page 21
  19. Nakane H, Ono K. Differential inhibitory effects of some catechin derivatives on the activities of HIV reverse transcriptase and cellular DNA and RNA polymerases, Biochemistry. 1990; 29: 2841–5p.
  20. Fassina G, Buffa A, Benelli R , et al. Polyphenolic antioxidant (−) – epigallocatechin–3–gallate from green tea as a candidate anti –HIV agent . AIDS. 2002; 16(6): 939–41p.
  21. Yamaguchi K, Honda M, Ikigai H, et al. Inhibitory effects of ( –)–epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV –1). Antiviral Res. 2002; 53: 19–34p.
  22. Williamson MP, McCormick TG, Nance CL, et al. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T–cell receptor, CD4: Potential for HIV – 1 therapy. J Allergy Clin Immunol . 2006; 118: 1369–74p.
  23. Sunthitikawinsakul A, Kongkathip N, Kongkathip B, et al. Anti–HIV–1 limonoid: first isolation from Clausena excavate. Phytother Res . 2003 17(9): 1101–3p.
  24. Singh IP, Bodiwala HS. Recent advanc es in anti –HIV natural products . Nat Prod Res. 2010; 27: 1781–1800p.
  25. Kongkathip B, Kongkathip N, Sunthitikawinsakul A, et al. Anti–HIV–1 constituents from Clausena excavata : Part II, Carbazoles and a pyranocoumarin. Phytother Res. 2005; 19: 728–31p.
  26. Mekkawy SE, Meselhy MR, Nakamura N, et al. Anti–HIV phorbol esters from the seeds of Croton tiglium , Phytochemistry. 2000; 53: 457–64p.
  27. Roth GN, Chandra A, Nair MG . Novel bioactivities of Curcuma longa constituents. J Nat Prod . 1998; 61: 542–5p.
  28. Mazumder A, Raghavan K, Weinstein J, et al. Inhibition of HIV type–1 integrase by curcumin. Biochem Pharmacol. 1995; 49: 1165–70p.
  29. Mazumder A, Neamati N, Sunder S, et al. Curcumin analogs with altered potencies against HIV –1 integrase as probes for biochemical mechanisms of drug action . J Med Chem. 1997; 40(19): 3057–63p.
  30. Sui Z, Salto R, Li J, et al. Inhibition of the HIV –1 and HIV –2 proteases by curcumin and curcumin boron complexes. Bioorg. Med. Chem . 1993; 1(6): 415–22p.
  31. Jordan WC, Drew CR. Curcumin -a natural herb with anti –HIV activity . J. Natl. Med. Assoc. 1996; 88(6): 333p.
  32. Cohly HHP, Asad S, Das SK, et al. Effect of antioxidant (turmeric, turmerin and curcumin) on human immunodeficiency virus. Int J Mol Sci. 2003; 4: 22–33p.
  33. Tewtrakul S, Subhadhirasakul S, Kummee S. Anti –HIV–1 integrase activity of medicinal plants used as s elf medication by AIDS patients . J Sci Techno. 2006; 28(4): 785–90p.
  34. Reutrakul V, Ja ipetch T, Yoosook C, et al. Cytotoxic and anti HIV–1 caged xanthones from the resins and fruits of Garcinia hanburyi. Planta Med . 2007; 73(1): 33–40p.
  35. Evans WC. Trease and Evans Pharmacognosy, 15th Edn. Saunders, Elsevier, USA: 2004; 434, 471, 478p.
  36. Ito M, Sato A, Hirabayashi K, et al. Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus ( HIV). Antiviral Res. 1988; 10 (6): 289–98p.
  37. Hattori T, Ikematsu S, Koito A, et al. Preliminary evidence for inhibitory effect of glycyrrhizin on HIV replication in patients with AIDS . Antiviral Res. 1989; 11: 255–61p.
  38. Hatano T, Yasuhara T, Miyamoto K, et al. Anti–human immunodeficiency virus phenolics from licorice . Chem Pharm Bull. 1988; 36: 2286–8p.
  39. Harada S. The broad anti –viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV –1 envelope. Biochem J . 2005; 15(392) : 191–9p.
  40. Wang Q, Ding ZH, Liu JK, et al. Xanthohumol, a novel anti –HIV–1 agent purified from hops Humulus lupulus . Antiviral Res. 2004; 64: 189–94p.
  41. Maury W, Price JP, Brindley MA, et al. Identification of light independent inhibition of HIV–1 infection through bioguided fractionation of Hypericum perforatum. Virol J. 2009; 6: 101p. Plants with Anti-HIV Potential Qamar Uddin et al. RRJoPC (2014) 11-22 © STM Journals 2014. All Rights Reserved Page 22
  42. Song WY, Ma YB, Bai X, et al. Two new compounds and anti –HIV active constituents from Illicium verum . Planta Med. 2007; 73(4): 372–5p.
  43. Igbinosa OO, Igbinosa EO, Aiyegoro OA. Antimicrobial activity and phytochemical screening of stem bark extracts from Jatropha curcas L. Afr J Pharma and Pharmacol . 2009; 3(2): 58– 62p.
  44. Dahake R, Roy S , Patil D, et al. Evaluation of anti –viral activity of Jatropha curcas leaf extracts against potentially drug –resistant HIV isolates . BMC Infectious Diseases . 2012; 12(1): 14p.
  45. Geuenich S, Goffine C, Venzke S, et al. Aqueous extracts from peppermint, sage and lemo n balm leaves display potent anti–HIV–1 activity by increasing the virion density . Retrovirology. 2008; 5: 27p.
  46. Zheng YT, Ben KL, Jin SW . Alpha– momorcharin inhibits HIV –1 replication in acutely but not chr onically infected T– lymphocytes. Zhongguo Yao Li Xue Bao. 1999; 20(3): 239–43p.
  47. Khare CP. Indian Medicinal Plants –An Illustrated Dictionary, 1st Indian Reprint, Springer I ndia Private Limited, New Delhi; 2007; 68, 230, 418, 707p.
  48. Puri M , Kaur I , Kanwar RK, et al. Ribosome inactivating proteins (RIPs) from Momordica charantia for anti–viral therapy. Curr Mol Med . 2009; 9(9): 1080–94p.
  49. Notka F, Meier G, Wagner R. Concerted inhibitory activities of Phyllanthus amarus on HIV r eplication in vitro and ex vivo . Antiviral Res . 2004; 64(2): 93–102p.
  50. Houghton PJ, Woldemariam TZ, O ’Shea S, et al. The anti –HIV activity of an aqueous extract and polyphenolic compounds of Phyllanthus amarus. J Pharma and Pharmacol. 1999; 51: 100p.
  51. Eldeen IMS, Seow EM, Abdullah R , et al. In vitro antibacterial, antioxidant, total phenolic contents and anti –HIV–1 reverse transcriptase activities of extracts of seven Phyllanthus sp. South African Journal of Botany. 2011; 77: 75–9p.
  52. Sagar KS, Chang CC, Wang WK, et al. Preparation and anti –HIV activities of retrojusticidin B analogs and azalignans . Bioorganic & Medicinal Chemistry . Elsevier: 2004; 12(15): 4045–54p.
  53. Li HY, Sun NJ, Kashiwada Y, et al. Anti–AIDS agents–Suberosol, a new C31 lanostane–type triterpene and anti –HIV principle from Polyalthia suberosa, J Nat Prod: 1993; 56(7): 1130–33p.
  54. Neurath AR , Strick N, Li Y Y, et al . Punica granatum (Pomegranate) juice provides an HIV –1 entry inhibitor and candidate topical microbicide, BMC Infect Dis: 2004; 4: 41p.
  55. Lin YM, Anderson H, Flavin MT , et al. In vitro anti–HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora, J Nat Prod: 1997; 60 (9): 884–8p.
  56. Ahn MJ, Kim CY, Lee JS, et al . Inhibition of HIV –1 integrase by galloyl glucoses from Terminalia chebula and flavonol gly coside gallates from Euphorbia pekinensis, Planta Med: 2002; 68(5): 457–9p.
Support